Industry: Pharmaceuticals, Biotechnology & Life Sciences
CEO:Mr. Michael S. Weiss Esq.
Full-time employees:245
City:New York
Address:2 Gansevoort Street
IPO:2018-11-23
CIK:
Website:
General Outlook
In simple terms, TG Therapeutics, Inc. has 151.41 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.967% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.100%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.137%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust -0.078% return, is a testament to TG Therapeutics, Inc.'s adeptness in optimizing resource deployment. TG Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.356%. Furthermore, the proficiency of TG Therapeutics, Inc. in capital utilization is underscored by a remarkable -0.069% return on capital employed.
Stock Prices
TG Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $13.59, while its low point bottomed out at $12.39. This variance in figures offers investors a lucid insight into the roller-coaster ride that is TG Therapeutics, Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
